Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.

Ryan DP, Eder JP Jr, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW.

Clin Cancer Res. 2004 Apr 1;10(7):2222-30.

2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
4.

Farnesyl transferase inhibitors in the treatment of breast cancer.

Kelland LR.

Expert Opin Investig Drugs. 2003 Mar;12(3):413-21. Review.

PMID:
12605564
5.

Farnesyltransferase inhibitors.

Hahn SM, Bernhard E, McKenna WG.

Semin Oncol. 2001 Oct;28(5 Suppl 16):86-93. Review.

PMID:
11706400
6.

BMS-214662 (Bristol-Myers Squibb).

Johnston SR.

IDrugs. 2003 Jan;6(1):72-8. Review.

PMID:
12789624
7.

A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.

Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P.

Clin Cancer Res. 2003 Nov 1;9(14):5101-12. Review.

8.
9.

Novel small molecule cyclin-dependent kinases modulators in human clinical trials.

Senderowicz AM.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95. Review.

PMID:
14508085
10.

Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.

Kurzrock R, Cortes J, Kantarjian H.

Semin Hematol. 2002 Oct;39(4 Suppl 3):20-4. Review.

PMID:
12447848
11.

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.

de Bono JS, Tolcher AW, Rowinsky EK.

Semin Oncol. 2003 Oct;30(5 Suppl 16):79-92. Review.

PMID:
14613029
12.

Farnesyl transferase inhibitors in clinical development.

Caponigro F, Casale M, Bryce J.

Expert Opin Investig Drugs. 2003 Jun;12(6):943-54. Review.

PMID:
12783599
13.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2142-8. Review.

14.
15.

Current status of clinical trials of farnesyltransferase inhibitors.

Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW.

Curr Opin Oncol. 2001 Nov;13(6):470-6. Review.

PMID:
11673687
16.

Preclinical and clinical evaluation of farnesyltransferase inhibitors.

Baum C, Kirschmeier P.

Curr Oncol Rep. 2003 Mar;5(2):99-107. Review.

PMID:
12583826
17.

Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.

Lancet JE, Rosenblatt JD, Karp JE.

Semin Hematol. 2002 Jul;39(3 Suppl 2):31-5. Review.

PMID:
12214291
18.

Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.

Santucci R, Mackley PA, Sebti S, Alsina M.

Cancer Control. 2003 Sep-Oct;10(5):384-7. Review.

19.

Ras inhibitors and radiation therapy.

Jones HA, Hahn SM, Bernhard E, McKenna WG.

Semin Radiat Oncol. 2001 Oct;11(4):328-37. Review.

PMID:
11677657
20.

DX-8951f: summary of phase I clinical trials.

De Jager R, Cheverton P, Tamanoi K, Coyle J, Ducharme M, Sakamoto N, Satomi M, Suzuki M; DX-8931f Investigators.

Ann N Y Acad Sci. 2000;922:260-73. Review.

PMID:
11193901
Items per page

Supplemental Content

Write to the Help Desk